Results 81 to 90 of about 20,402 (244)
Background Pompe disease is caused by pathogenic variants in the GAA gene, resulting in lysosomal acid α-glucosidase (GAA) deficiency. The prevalence of Pompe disease is not well-defined, and estimates vary by geographic region.
Roberto Giugliani +6 more
doaj +1 more source
Psidium guajava leaves contain potent bioactive compounds like quercetin, myricetin, and triterpenoids that show antioxidant, antidiabetic, anti‐inflammatory, and anticancer effects. They act by modulating NF‐κB, PPARγ, and α‐glucosidase and by inducing apoptosis and cell cycle arrest.
Muhammad Waqar +10 more
wiley +1 more source
Background: Pompe disease is a rare lysosomal glycogen storage disorder linked to the acid alpha-glucosidase gene (GAA). A wide clinical and genetic variability exists between patients from different ethnic populations, and the genotype-phenotype ...
Hua-Xu Liu +4 more
doaj +1 more source
Sleep deprivation accelerates the progression of MASLD and IR by up‐regulating the expression of miR‐3572‐5p and down‐regulating the expression of miR‐183‐5p in circulating exosomes, thereby inhibiting fatty acid β‐oxidation and disrupting insulin signaling pathways. Abstract Sleep deprivation (SD) threatens human health and increases the prevalence of
Xinxin Xu +10 more
wiley +1 more source
Late-onset glycogen storage disease type 2.
Glycogenosis II (GSDII) is an autosomal recessive lysosomal storage disorder resulting from acid alpha-glucosidase (GAA) deficiency, subsequent lysosomal accumulation of glycogen in muscles, impairment of autophagic processes and progressive cardiac ...
Cotelli M. S. +8 more
core +1 more source
The regulation of stem cell fate and its application in neural regeneration
Regulating stem cell fate is crucial for neural regeneration. This review summarizes key physical, biological, and chemical strategies and their applications in repairing nerve injuries, providing new insights for regenerative medicine. Abstract Regulating the fate of stem cells (SCs) is a key technical problem in the field of regenerative medicine and
Yuexin He +3 more
wiley +1 more source
Enzyme replacement therapy (ERT) is the only approved disease-modifying treatment modality for Pompe disease, a rare, inherited metabolic disorder caused by a deficiency in the acid α-glucosidase (GAA) enzyme that catabolizes lysosomal glycogen.
Barry J. Byrne +17 more
doaj +1 more source
LEUKOCYTE DEBRANCHING ENZYME IN GLYCOGEN STORAGE DISEASE
In recent years the classification of glycogen storage disease has been based on the demonstration of a specific enzyme defect for each type (1-4). Type I, glycogenosis or von Gierke's disease, results from the lack of glucose 6-phosphatase (1 ...
E. Williams, Esther M. Kendig, James B
core
Glycogen storage disease type II: Birth prevalence agrees with predicted genotype frequency
OBJECTIVES: To compare the overall birth prevalence of diagnosed glycogen storage disease type II (GSD II) with the predicted frequency based on mutation screening, in order to determine whether GSD II is an underdiagnosed condition, and to analyze which
Wokke, J. H. +47 more
core +1 more source
GSK3β drives early diabetic tubulopathy via TFEB‐mediated mitochondrial dysfunction
Mitochondrial dysfunction, including mitochondrial biogenesis, mitophagy, dynamics and oxidative stress, occurs in the early stages of diabetic tubulopathy, which precede proteinuria and renal histological changes. GSK3β is a potential novel biomarker for the prediction of diabetic tubulopathy.
Lan Yao +10 more
wiley +1 more source

